Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change
Cumberland Pharmaceuticals' stock is one of the leading gainers today, surging over 90% in value. Moreover, in the past month we've seen the stock jumping a whopping 101%.
Thanks mostly to FDA approval of a supplementary New Drug Application (sNDA) for Acetadote (N-acetylcysteine for injection), Cumberland stock has been on a monumental run in December 2024. This approval streamlines the dose schedule, therefore improving safety and efficiency in treating liver damage connected to acetaminophen.
- Warning! GuruFocus has detected 2 Warning Sign with CPIX.
Hospitals all around have adopted the simplified strategy to lower medication mistakes and severe non-allergic anaphylactoid responses without sacrificing efficacy. This regulatory landmark has raised investor confidence, which has driven the stock price of the company much higher. Cumberland's development chances are significantly improved by the FDA Orphan Drug and Rare Pediatric Disease Designations for its Duchenne muscular dystrophy medication.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10